|   From the Trenches

Controlling Your Destiny: Why Investment in Manufacturing Capabilities Makes Sense


Manufacturing of medicines based on biology is complex. Viral vector manufacturing to produce gene therapy constructs, vaccines and oncolytic viruses is especially intricate. Most early stage companies use contract manufacturing organizations until real clinical proof of principle is achieved as a logical decision inflection point for investing in in-house manufacturing, versus continuing to use a CMO for pivotal studies and launch.

By Philip Astley-Sparke, CEO of Replimune, as part of the From The Trenches feature of LifeSciVC.

Read more.